New targets and therapies for gastrointestinal stromal tumors

References

• Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382:973–983.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(Suppl 2):S1–41.
   PubMed Web of Science ®Google Scholar
• Wozniak A, Rutkowski P, Schöffski P, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a European multicenter analysis based on ConticaGIST. Clin Cancer Res. 2014;20:6105–6116.
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–1134.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang YK, et al. GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–4349.
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093–1103.
   PubMed Web of Science ®Google Scholar
• Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28:1247–1253.
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182–4190.
   PubMed Web of Science ®Google Scholar
• Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12:1743–1749.
   PubMed Web of Science ®Google Scholar
• Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216:64–74.
   PubMed Web of Science ®Google Scholar
• Quattrone A, Wozniak A, Dewaele B, et al. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. Mod Pathol. 2014;27:1510–1520.
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005;128:270–279.
   PubMed Web of Science ®Google Scholar
• Sciot R, Debiec-Rychter M. GIST under imatinib therapy. Semin Diagn Pathol. 2006;23:84–90.
   PubMed Web of Science ®Google Scholar
• Javidi-Sharifi N, Traer E, Martinez J, et al. Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance. Cancer Res. 2015;75:880–891.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Cooke L, Riley C, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene. 2007;26:3909–3919.
   PubMed Web of Science ®Google Scholar
• Cohen NA, Zeng S, Seifert AM, et al. Pharmacological inhibition of KIT activates MET signaling in gastrointestinal stromal tumors. Cancer Res. 2015;75:2061–2070.
   PubMed Web of Science ®Google Scholar
• Dubreuil P, Letard S, Ciufolini M, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009;4:e7258.
   PubMed Web of Science ®Google Scholar
• LeCesne A, Blay J, Bui BN, et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastrointestinal stromal tumors (GIST). Eur J Cancer. 2010;46:1344–1351.
   PubMed Web of Science ®Google Scholar
• Adenis A, Blay JY, Bui-Nguyen B, et al. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. Ann Oncol. 2014;25:1762–1769.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Jones R, Schoffski P, et al. Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFR alpha activation loop mutants in advanced gastrointestinal stromal tumor (GIST). Eur J Cancer. 2016;68:Abstract 6LBA.
   Google Scholar
• Von Mehren M, Tetzlaff ED, Macaraeg M, et al. Dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations. J Clin Oncol. 2016;34:Abstract 11010.
   Web of Science ®Google Scholar
• Janku F, George S, Razak A, et al. DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study. Eur J Cancer. 2016;68:Abstract LBA7.
   Google Scholar
• Kang Y, Yoo C, Ryoo B, et al. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. Br J Cancer. 2013;109:2309–2315.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Sutton GR, Arteta-Bulos R, et al. Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2014;73:467–473.
   PubMed Web of Science ®Google Scholar
• Mehren M, George S, Heinrich MC, et al. Results of SARC 022, a Phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST). J Clin Oncol. 2014;32(Suppl.):Abstract10507.
   Google Scholar
• Ganjoo KN, Villalobos VM, Kamaya A, et al. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol. 2014;25:236–240.
   PubMed Web of Science ®Google Scholar
• Mir O, Cropet C, Toulmonde M, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol. 2016;17:632–641.
   PubMed Web of Science ®Google Scholar
• Heinrich CM, Von Mehren M, Demetri GD, et al. Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TIK) failure: results from a phase 2 study. J Clin Oncol. 2015;33:Abstract 10535.
   Web of Science ®Google Scholar
• Glod J, Arnaldez F, Wiener L, et al. A phase II trial of vandetanib (ZD6474) in children and adults with wild-type gastrointestinal stromal tumors. J Clin Oncol. 2016;34:Abstract 11009.
   Web of Science ®Google Scholar
• Judson I, Scurr M, Gardner K, et al. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clin Cancer Res. 2014;20:3603–3612.
   PubMed Web of Science ®Google Scholar
• Joensuu H, De Braud F, Grignagni G, et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer. 2011;104:1686–1690.
   PubMed Web of Science ®Google Scholar
• Zhou A, Zhang W, Chang C, et al. Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Cancer Chemother Pharmacol. 2013;72:1043–1053.
   PubMed Web of Science ®Google Scholar
• Yap TA, Arkenau HT, Camidge DR, et al. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clin Cancer Res. 2013;19:909–919.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Shoushtari AN, Keohan ML, et al. Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: A phase Ib study of dasatinib plus ipilimumab. Clin Cancer Res. 2017;23:2972–2980.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Griffith D. McKinley A. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin. Cancer Res. 2012;18(16):4375–4384.
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Bardsley MR, Toyomasu Y, et al. Platelet-derived growth factor receptor-α regulates proliferation of gastrointestinal stromal tumor cells with mutations in KIT by stabilizing ETV1. Gastroenterology. 2015;149:420–432.
   PubMed Web of Science ®Google Scholar
• Evans EK, Hodous BL, Gardino A, et al. BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants. Cancer Res. 2015;75:Abstract 791.
   Google Scholar
• Gebreyohannes Y, Wozniak A, Zhai ME et al. Robust efficacy of BLU-285, a novel, potent and highly selective inhibitor of Exon 17 Mutant KIT and PDGFRα D842V, in patient-derived xenograft models of gastrointestinal stromal tumor (GIST). AACR Annual Meeting 2017; Abstract 687
   Google Scholar
• Gebreyohannes YK, Wozniak A, Wellens J et al. PLX9486 shows anti-tumor efficacy in a patient-derived gastrointestinal stromal tumor (GIST) xenograft model resistant to standard tyrosine kinase inhibitors (TKI). Connective Tissue Oncology Society 20th Annual Meeting 2015;Abstract 05.
   Google Scholar
• Gebreyohannes YK, Schöffski P, Van Looy T, et al. Cabozantinib is active against human gastrointestinal stromal tumor xenografts carrying different KIT mutations. Mol Cancer Ther. 2016;15:2845–2852.
   PubMed Web of Science ®Google Scholar
• Li F, Huynh H, Li X, et al. FGFR-mediated reactivation of MAPK signaling attenuates antitumor effects of imatinib in gastrointestinal stromal tumors. Cancer Discov. 2015;5:438–451.
   PubMed Web of Science ®Google Scholar
• Yoo C, Ryu MH, Na YS, et al. Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors. Ann Oncol. 2014;25:2272–2277.
   PubMed Web of Science ®Google Scholar
• Gebreyohannes YK, Van Looy T, Wozniak A, et al. Anti-tumor effects of dovitinib, a multi-target kinase inhibitor, in patient-derived gastrointestinal stromal tumor (GIST) xenograft models. Cancer Res. 2015;75:Abstract 775.
   Web of Science ®Google Scholar
• Tarn C, Rink L, Merkel E, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA. 2008;105:8387–8392.
   PubMed Web of Science ®Google Scholar
• Janeway KA, Zhu MJ, Barretina J, et al. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer. 2010;127:2718–2722.
   PubMed Web of Science ®Google Scholar
• Lasota J, Wang Z, Kim SY, et al. Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am J Surg Pathol. 2013;37:114–119.
   PubMed Web of Science ®Google Scholar
• Chen W, Kuang Y, Qiu HB, et al. Dual targeting of insulin receptor and KIT in imatinib-resistant gastrointestinal stromal tumors. Cancer Res. 2017 July 31 published online. DOI:10.1158/0008-5472
   Google Scholar
• Smith NR, Baker D, James NH, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res. 2010;16:3548–3561.
   PubMed Web of Science ®Google Scholar
• McAuliffe JC, Lazar AJ, Yang D, et al. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate. Clin Cancer Res. 2007;13:6727–6734.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Corless C, et al. A SWOG phase III randomized study of imatinib, with or without bevacizumab, in patients with untreated metastatic or unresectable gastrointestinal stromal tumors. Oncologist. 2015;20:1353–1354.
   PubMed Web of Science ®Google Scholar
• Garner AP, Gozgit JM, Anjum R, et al. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014;20:5745–5755.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, McGarry L, Kerstein D, et al. Real-world outcomes of ponatinib in treatment of advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure. J Clin Oncol. 2017;35:Abstract e22508.
   Web of Science ®Google Scholar
• Yang Y, Ikezoe T, Nishioka C, et al. ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib. Cancer Sci. 2006;97:1404–1409.
   PubMed Web of Science ®Google Scholar
• Brave SR, Ratcliffe K, Wilson Z, et al. Assessing the activity of cediranib, a VEGFR-2/-3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR-family. Mol Cancer Ther. 2011;10:861–873.
   PubMed Web of Science ®Google Scholar
• Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18:516–523.
   PubMed Web of Science ®Google Scholar
• Rossi F, Yozgat Y, De Stanchina E, et al. Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res. 2010;8:1271–1283.
   PubMed Web of Science ®Google Scholar
• Obata Y, Horikawa K, Takahashi T, et al. Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors. Oncogene. 2017;36:3661–3672.
   PubMed Web of Science ®Google Scholar
• Sakurama K, Noma K, Takaoka M, et al. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor. Mol Cancer Ther. 2009;8:127–134.
   PubMed Web of Science ®Google Scholar
• Koon N, Schneider-Stock R, Sarlomo-Rikala M, et al. Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut. 2004;53:235–240.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Serada S, Ako M, et al. New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis. Int J Cancer. 2013;133:2737–2743.
   PubMed Web of Science ®Google Scholar
• Jones SF, Siu LL, Bendell JC, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015;33:1100–1107.
   PubMed Web of Science ®Google Scholar
• Dewaele B, Wasag B, Cools J, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res. 2008;14:5749–5758.
   PubMed Web of Science ®Google Scholar
• Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66:473–481.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–619.
   PubMed Web of Science ®Google Scholar
• Patel S. Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway. Curr Oncol Rep. 2013;15:386–395.
   PubMed Web of Science ®Google Scholar
• Bauer S, Duensing A, Demetri GD, et al. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene. 2007;26:7560–7568.
   PubMed Web of Science ®Google Scholar
• Lasota J, Felisiak-Golabek A, Wasag B, et al. Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases. Mod Pathol. 2016;29:275–282.
   PubMed Web of Science ®Google Scholar
• Floris G, Wozniak A, Sciot R, et al. A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. Clin Cancer Res. 2013;19:620–630.
   PubMed Web of Science ®Google Scholar
• Van Looy T, Wozniak A, Floris G, et al. Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy. Clin Cancer Res. 2014;20:6071–6082.
   PubMed Web of Science ®Google Scholar
• Bozic I, Reiter JG, Allen B, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife. 2013;2:e00747.
   PubMed Web of Science ®Google Scholar
• Conley AP, Araujo D, Ludwig J, et al. A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol. 2009;15S:Abstract 10563.
   Google Scholar
• Schöffski P, Reichardt P, Blay JY, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). Ann Oncol. 2010;21:1990–1998.
   PubMed Web of Science ®Google Scholar
• Chi P, Qin L-X, D’Angelo SP, et al. A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST). J Clin Oncol. 2015;33:Abstract 10507.
   Web of Science ®Google Scholar
• Zook P, Pathak HB, Belinsky MG, et al. Combination of imatinib mesylate and AKT Inhibitor provides synergistic effects in preclinical study of gastrointestinal stromal tumor. Clin Cancer Res. 2017;23:171–180.
   PubMed Web of Science ®Google Scholar
• Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–1759.
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Kondo Y, Fujiwara K, et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatedylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005;65:3336–3346.
   PubMed Web of Science ®Google Scholar
• Yazbeck VY, Buglio D, Georgakis GV, et al. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol. 2008;36:443–450.
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, Nicoletti G, Nanni C, et al. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. J Exp Clin Cancer Res. 2010;29:173.
   PubMed Web of Science ®Google Scholar
• Piovesan C, Fumagalli E, Coco P, et al. Response to sirolimus in combination to tirosine kinase inhibitors (TKI) in three cases of PDGFRA-D842V metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2009;15s:27.
   Google Scholar
• Slotkin EK, Patwardhan PP, Vasudeva SD, et al. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma. Mol Cancer Ther. 2015;14:395–406.
   PubMed Web of Science ®Google Scholar
• Mühlenberg T, Ketzer J, Fletcher JA, et al. Novel mTOR inhibitor MLN0128 inhibits imatinib-resistant GIST more potently than rapalogues by abrogating AKT and 4EBP1 activation. AACR Annual Meeting 2016; Abstract 337
   Google Scholar
• Miranda C, Nucifora M, Molinari F, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2012;18:1769–1776.
   PubMed Web of Science ®Google Scholar
• Lasota J, Xi L, Coates T, et al. No KRAS mutations found in gastrointestinal stromal tumors (GISTs): molecular genetic study of 514 cases. Mod Pathol. 2013;26:1488–1491.
   PubMed Web of Science ®Google Scholar
• Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47:853–859.
   PubMed Web of Science ®Google Scholar
• Hostein I, Faur N, Primois C, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133:141–148.
   PubMed Web of Science ®Google Scholar
• Falchook GS, Trent JC, Heinrich MC, et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 2013;4:310–315.
   PubMed Web of Science ®Google Scholar
• Ran L, Sirota I, Cao Z, et al. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discov. 2015;5:304–315.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013;14:e358–69.
   PubMed Web of Science ®Google Scholar
• Bauer S, Yu LK, Demetri GD, et al. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006;66:9153–9161.
   PubMed Web of Science ®Google Scholar
• Floris G, Debiec-Rychter M, Wozniak A, et al. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. Mol Cancer Ther. 2011;10:1897–1908.
   PubMed Web of Science ®Google Scholar
• Floris G, Sciot R, Wozniak A, et al. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. Clin Cancer Res. 2011;17:5604–5614.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Chugh R, Rosen LS, et al. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013;19:6020–6029.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Le Cesne A, Von Mehren M, et al. Final results from a phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. Gastrointestinal Cancers Symposium 2010:Abstract 64
   Google Scholar
• Dickson MA, Okuno SH, Keohan ML, et al. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol. 2013;24:252–257.
   PubMed Web of Science ®Google Scholar
• Bauer S, Hilger RA, Mühlenberg T, et al. Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer. 2014;110:1155–1162.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Kindler H, Gelderblom H, et al. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Ann Oncol. 2017;28:541–546.
   PubMed Web of Science ®Google Scholar
• Smyth T, Van Looy T, Curry JE, et al. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. Mol Cancer Ther. 2012;11:1799–1808.
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Kwak E, Dezube BJ, et al. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors. Clin Cancer Res. 2015;21:87–97.
   PubMed Web of Science ®Google Scholar
• Wagner AJ, Agulnik M, Heinrich MC, et al. Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. Eur J Cancer. 2016;61:94–101.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Bauer TM, Lamar R, et al. A phase 2 study of the Hsp90 Inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors. Cancer Invest. 2016;34.
   Web of Science ®Google Scholar
• Chiang N-J, Yeh K-H, Chiu C-F, et al. Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy. J Clin Oncol. 2016;34:Abstract 134.
   Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38–51.
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124:30–39.
   PubMed Web of Science ®Google Scholar
• Mühlenberg T, Zhang Y, Wagner AJ, et al. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res. 2009;69:6941–6950.
   PubMed Web of Science ®Google Scholar
• Floris G, Debiec-Rychter M, Sciot R, et al. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res. 2009;15:4066–4076.
   PubMed Web of Science ®Google Scholar
• Chi P, Chen Y, Zhang L, et al. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 2010;467:849–853.
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349–360.
   PubMed Web of Science ®Google Scholar
• Bauer S, Parry JA, Mühlenberg T, et al. Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells. Cancer Res. 2010;70:150–159.
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17:93–115.
   PubMed Web of Science ®Google Scholar
• Schmieder M, Wolf S, Danner B, et al. p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome. Neoplasia. 2008;10:1154–1162.
   PubMed Web of Science ®Google Scholar
• Saponara M, Urbini M, Astolfi A, et al. Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS). Oncotarget. 2015;6:42243–42257.
   PubMed Web of Science ®Google Scholar
• Romeo S, Debiec-Rychter M, Van Glabbeke M, et al. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res. 2009;15:4191–4198.
   PubMed Web of Science ®Google Scholar
• Lagarde P, Pérot G, Kauffmann A, et al. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res. 2012;18:826–838.
   PubMed Web of Science ®Google Scholar
• Logan JE, Mostofizadeh N, Desai AJ, et al. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013;33:2997–3004.
   PubMed Web of Science ®Google Scholar
• Young RJ, Waldeck K, Martin C, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res. 2014;27:590–600.
   PubMed Web of Science ®Google Scholar
• Lvin JA, Gay LM, Ort R, et al. Clinical benefit in response to palbociclib treatment in refractory uterine leiomyosarcomas with a common CDKN2A alteration. Oncologist. 2017;22:416–421.
   PubMed Web of Science ®Google Scholar
• Yeh CN, Yen CC, Chen YY, et al. Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors. Oncotarget. 2014;5:4071–4086.
   PubMed Web of Science ®Google Scholar
• Dickson MA, Mahoney MR, Tap WD, et al. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. Ann Oncol. 2016;27:1855–1860.
   PubMed Web of Science ®Google Scholar
• Tornillo L, Duchini G, Carafa V, et al. Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest. 2005;85:921–931.
   PubMed Web of Science ®Google Scholar
• Henze J, Mühlenberg T, Simon S, et al. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One. 2012;7:e37776.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Yamamoto H, Yao T, et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol. 2005;36:828–837.
   PubMed Web of Science ®Google Scholar
• Van Dongen M, Savage ND, Jordanova ES, et al. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromaltumors. Int J Cancer. 2010;127:899–909.
   PubMed Web of Science ®Google Scholar
• Rusakiewicz S, Semeraro M, Sarabi M, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013;73:3499–3510.
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Mamessier E, et al. PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology. 2015;4:e1002729.
   PubMed Web of Science ®Google Scholar
• Seifert AM, Zeng S, Zhang JQ, et al. PD-1/PD-L1 blockade enhances t-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2017;23:454–465.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17:1094–1100.
   PubMed Web of Science ®Google Scholar
• Edris B, Willingham SB, Weiskopf K, et al. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proc Natl Acad Sci U S A. 2013;110:3501–3506.
   PubMed Web of Science ®Google Scholar
• Van Looy T, Wozniak A, Floris G, et al. Therapeutic efficacy assessment of CK6, a monoclonal KIT antibody, in a panel of gastrointestinal stromal tumor xenograft models. Transl Oncol. 2015;8:112–118.
   PubMed Web of Science ®Google Scholar
• Boichuk S, Lee DJ, Mehalek KR, et al. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. Cancer Res. 2014;74:1200–1213.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Jeffers M, Reichardt P, et al. Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: correlating genotype with clinical outcomes. J Clin Oncol. 2013;31:10503.
   Web of Science ®Google Scholar
• Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548–554.
   PubMed Web of Science ®Google Scholar
• Tan Y, Trent JC, Wilky BA, et al. Current status of immunotherapy for gastrointestinal stromal tumor. Cancer Gene Ther. 2017;24:130–133.
   PubMed Web of Science ®Google Scholar